Adalvo is excited to announce the launch of Gabapentin ER 300/600 mg in South Korea, in collaboration with our sister company, Lotus.
Our product is based on the reference brand, Neurontin Hard Capsule 300mg, and Neurontin Film Coated Tablet 600mg, and is indicated in the treatment of Postherpetic Neuralgia (PHN), offering significant patient convenience with one daily dosing.
Gabapentin ER has been launched in collaboration with Adalvo's sister company Lotus, an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
This product has a global market value of $1.24bn, with total sales in Korea climbing up to $36Mn, according to IQVIA 2022.
This effective collaboration has allowed Adalvo to successfully implement a clearly defined IP pathway and provide the opportunity to be amongst the first wave of generic launches for this high-value product in South Korea.
Anil Okay, CEO of Adalvo, states, "Through our collaboration with Lotus Pharma, we've not only utilised our combined expertise but also leveraged our mutual commitment to innovation within the pharmaceutical industry. This launch not only underscores our dedication to offering effective treatment options but also highlights the exceptional synergy between Adalvo and Lotus Pharma. Collectively, we've laid a robust groundwork for delivering invaluable and accessible medicine to patients around the globe."
Petar Vazharov, CEO of Lotus, added," We are proud to announce the highly anticipated launch of Gralise ER (Extended-Release) in South Korea. The launch of this product not only significantly enhances Lotus’ offering in the field of neurology in Korea, but also demonstrates Lotus’ ability to add more innovative and complex products to its portfolio. This is another milestone in our transformation from a pure-play generic company in Asia to a global pharma platform with well diversified portfolio including generics, Brands, New Chemical Entities (NCEs), 505b(2)s and other complex pharma products.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities.
The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Lotus Pharmaceuticals
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safer, and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.